KarXT for acute psychosis in Japanese adults with schizophrenia
About this title
Read the official source — NCT06882785This study evaluates the safety and effectiveness of KarXT for people with schizophrenia.
Understand this study
What is this study about?
This study evaluates the safety and effectiveness of KarXT for people with schizophrenia.
Who could participate?
Listed age limits: 18 years to 65 years.
- Listed locations
- Kōnan and 55 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
What to know before participating
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 250
- Sponsor
- Bristol-Myers Squibb
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug, Other
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Japan
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT06882785
- Official title
Show the full official title
A Phase 3, Randomized, Two-part Study With a 5-week Double-blind Part (Randomized, Parallelgroup, Placebo-controlled) Followed by a 52-week Open-label Extension Part to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Patients With Diagnostic and Statistical Manual of Mental Disorders-Fifth Edition (DSM-5) Schizophrenia
Recruitment & locations
Kōnan · Nagoya · Toyoake
48 more locations
- Ichikawa
- Iizuka
- Kitakyushu
- Omuta
- Aizu-Wakamatsu
- Toki
- Kure
- Sapporo
- Hadano-shi
- Hiratsuka
- Sagamihara
- Yokohama
- Kumamoto
- Yatsushiro
- Maizuru
- Miyakonojō
- Komoro
- Matsumoto
- Ginowan
- Hirakata
- Moriguchi
- Neyagawa
- Takatsuki
- Karatsu-shi
- Tosu
- Kumagaya
- Shimotsuga
- Shimotsuke
- Utsunomiya
- Hachiōji
- Kodaira
- Machida
- Ōta-ku
- Setagaya City
- tabashi City
- Ube
- Chiba
- Fukuoka
- Kyoto
- Miyazaki
- Okayama
- Okinawa
- Osaka
- Saitama
- Tokushima
- Tottori
- Wakayama
- Yamagata
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety and effectiveness of KarXT for people with schizophrenia.
Who is behind this study?
The study sponsor is Bristol-Myers Squibb, a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including KarXT.
Who can participate?
Listed age limits: 18 years to 65 years.
Is this study still recruiting?
The registry lists this study as recruiting.
